Depending on a variety of factors such as how many prior therapies you’ve received, your health status, and/or the stage of your multiple myeloma, your doctor may consider the following treatment options:
Multiple Myeloma Drug Therapies
- Immunomodulatory agents, such as Revlimid® (lenalidomide) and Pomalyst® (pomalidomide)
- Proteasome inhibitors (PIs), such as Velcade® (bortezomib) and Kyprolis® (carfilzomib)
- Histone deacetylase (HDAC) inhibitor Farydak® (panobinostat)
- Monoclonal antibodies, such as DARZALEX®
- Corticosteroids, such as dexamethasone and prednisone, in combination with other products
Other Multiple Myeloma Therapies
- Stem cell transplant
It is important to discuss your treatment options with your healthcare team. Here is a list of questions to ask your healthcare team.
For most people, treating multiple myeloma is an ongoing process due to the potential for disease recurrence or resistance to treatment. When your multiple myeloma relapses, you and your healthcare team may want to discuss additional treatment options.
What is DARZALEX®?
DARZALEX® is a prescription medicine used to treat multiple myeloma:
- In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma
- Alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent
DARZALEX® is the first monoclonal antibody approved for people with this type of cancer.
A monoclonal antibody is a man-made molecule that binds to substances in the body, including cancer cells. Monoclonal antibodies work with your immune system.
Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation. Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc. Farydak® is a registered trademark of Novartis Pharmaceuticals Corporation. Kyprolis® is a registered trademark of Onyx Pharmaceuticals, Inc.